Endoscopic and pathological aspects of colitis-associated dysplasia

Nature Reviews Gastroenterology and Hepatology

Volumn 6, Issue 11, 2009, Pages 671-678

  van Schaik, Fiona D M ^a   Offerhaus, G Johan A ^a   Schipper, Marguerite E I ^a   Siersema, Peter D ^a   Vleggaar, Frank P ^a   Oldenburg, Bas ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOFLUORESCENCE IMAGING; CHROMOENDOSCOPY; CLINICAL DECISION MAKING; COLITIS; COLON RESECTION; COLONOSCOPY; COLORECTAL CANCER; CONFOCAL MICROSCOPY; DISEASE SURVEILLANCE; DYSPLASIA; ENDOSCOPY; HISTOPATHOLOGY; HUMAN; NARROW BAND IMAGING; POLYPECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

COLITIS; COLON; COLONOSCOPY; COLORECTAL NEOPLASMS; HUMANS; PRECANCEROUS CONDITIONS;

EID: 70449520489     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2009.162     Document Type: Review

References (72)

1. Itzkowitz, S. H. & Yio, X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: The role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 287, G7-17 (2004).
2. Rutter, M. et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126, 451-459 (2004).
3. Gupta, R. B. et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: A cohort study. Gastroenterology 133, 1099-1105 (2007).
4. Levin, B. Ulcerative colitis and colon cancer: Biology and surveillance. J. Cell Biochem. Suppl. 16G, 47-50 (1992).
5. Eaden, J. A., Abrams, K. R. & Mayberry, J. F. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut 48, 526-535 (2001).
6. Bernstein, C. N., Blanchard, J. F., Kliewer, E. & Wajda, A. Cancer risk in patients with inflammatory bowel disease: A population-based study. Cancer 91, 854-862 (2001).
7. Gillen, C. D., walmsley, R. S., Prior, P., Andrews, H. A. & Allan, R. N. Ulcerative colitis and Crohn's disease: A comparison of the colorectal cancer risk in extensive colitis. Gut 35, 1590-1592 (1994).
8. SEER Cancer Statistics Review 1975-2006 (updated May 29, 2009). http://seer.cancer.gov/csr/1975_2006/index.html
9. Eaden, J. A. & Mayberry, J. F. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 51 (suppl. 5), V10-V12 (2002).
10. Winawer, S. et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 124, 544-560 (2003).
11. Blackstone, M. O., Riddell, R. H., Rogers, B. H. & Levin, B. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: An indication for colectomy. Gastroenterology 80, 366-374 (1981).
12. Torres, C., Antonioli, D. & Odze, R. D. Polypoid dysplasia and adenomas in inflammatory bowel disease: A clinical, pathologic, and follow-up study of 89 polyps from 59 patients. Am. J. Surg. Pathol. 22 275-284 (1998).
13. Bernstein, C. N., Shanahan, F. & Weinstein, W. M. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 343, 71-74 (1994).
14. Riddell, R. H. et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum. Pathol. 14, 931-968 (1983).
15. Eaden, J., Abrams, K., McKay, H., Denley, H. & Mayberry, J. Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J. Pathol. 194, 152-157 (2001).
16. Melville, D. M. et al. Observer study of the grading of dysplasia in ulcerative colitis: Comparison with clinical outcome. Hum. Pathol. 20, 1008-1014 (1989).
17. Karlen, P. et al. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 42, 711-714 (1998).
18. Connell, W. R. et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 107, 934-944 (1994).
19. Friedman, S., Rubin, P. H., Bodian, C., Harpaz, N. & Present, D. H. Screening and surveillance colonoscopy in chronic Crohn's colitis: results of a surveillance program spanning 25 years. Clin. Gastroenterol. Hepatol. 6, 993-998 (2008).
20. Rutter, M. D. et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 130, 1030-1038 (2006).
21. Claessen, M. M., Vleggaar, F. P., Tytgat, K. M., Siersema, P. D. & van Buuren, H. R. High lifetime risk of cancer in primary sclerosing cholangitis. J. Hepatol. 50, 158-164 (2009).
22. Broome, U., Lofberg, R., Veress, B. & Eriksson, L. S. Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential. Hepatology 22, 1404-1408 (1995).
23. Rubin, C. E. et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 103, 1611-1620 (1992).
24. Lutgens, M. W. et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut 57, 1246-1251 (2008).
25. Rutter, M. D. et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest. Endosc. 60, 334-339 (2004).
26. Odze, R. D., Farraye, F. A., Hecht, J. L. & Hornick, J. L. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin. Gastroenterol. Hepatol. 2 534-541 (2004).
27. Odze, R. D., Brown, C. A., Hartmann, C. J., Noffsinger, A. E. & Fogt, F. Genetic alterations in chronic ulcerative colitis-associated adenoma-like DALMs are similar to non-colitic sporadic adenomas. Am. J. Surg. Pathol. 24, 1209-1216 (2000).
28. Fogt, F. et al. Distinction between dysplasia-associated lesion or mass (DALM) and adenoma in patients with ulcerative colitis. Hum. Pathol. 31, 288-291 (2000).
29. Matsumoto, T. et al. Endoscopic and chromoendoscopic atlas featuring dysplastic lesions in surveillance colonoscopy for patients with long-standing ulcerative colitis. Inflamm. Bowel. Dis. 14 259-264 (2008).
30. Blonski, W. et al. Is dysplasia visible during surveillance colonoscopy in patients with ulcerative colitis? Scand. J. Gastroenterol. 43, 698-703 (2008).
31. Ullman, T., Croog, V., Harpaz, N., Sachar, D. & Itzkowitz, S. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 125, 1311-1319 (2003).
32. Befrits, R., Ljung, T., Jaramillo, E. & Rubio, C. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: A follow-up study. Dis. Colon Rectum 45, 615-620 (2002).
33. Jess, T. et al. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: A population-based study from Olmsted County, Minnesota. Inflamm. Bowel Dis. 12, 669-676 (2006).
34. Dixon, M. F. et al. Observer variation in the assessment of dysplasia in ulcerative colitis. Histopathology 13, 385-397 (1988).
35. Odze, R. D. et al. Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology. Mod. Pathol. 15, 379-386 (2002).
36. Pietsch, E. C., Sykes, S. M., McMahon, S. B. & Murphy, M. E. The p53 family and programmed cell death. Oncogene 27, 6507-6521 (2008).
37. Ajioka, Y., Watanabe, H. & Matsuda, K. Over-expression of p53 protein in neoplastic changes in ulcerative colitis: Immunohistochemical study. J. Gastroenterol. 30 (Suppl. 8), 33-35 (1995).
38. Brentnall, T. A. et al. Mutations in the p53 gene: An early marker of neoplastic progression in ulcerative colitis. Gastroenterology 107, 369-378 (1994).
39. Harpaz, N. et al. p53 protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma. Hum. Pathol. 25, 1069-1074 (1994).
40. Sato, A. & MacHinami, R. p53 immunohistochemistry of ulcerative colitis-associated with dysplasia and carcinoma. Pathol. Int. 49, 858-868 (1999).
41. Andersen, S. N., Rognum, T. O., Bakka, A. & Clausen, O. P. Ki-67: A useful marker for the evaluation of dysplasia in ulcerative colitis. Mol. Pathol. 51, 327-332 (1998).
42. Wong, N. A., Mayer, N. J., MacKell, S., Gilmour, H. M. & Harrison, D. J. Immunohistochemical assessment of Ki67 and p53 expression assists the diagnosis and grading of ulcerative colitis-related dysplasia. Histopathology 37, 108-114 (2000).
43. Shinozaki, M. et al. High proliferative activity is associated with dysplasia in ulcerative colitis. Dis. Colon Rectum 43, S34-S39 (2000).
44. Sjoqvist, U., Ost, A. & Lofberg, R. Increased expression of proliferative Ki-67 nuclear antigen is correlated with dysplastic colorectal epithelium in ulcerative colitis. Int. J. Colorectal Dis. 14, 107-113 (1999).
45. Aust, D. E. et al. Altered distribution of beta-catenin, and its binding proteins E-cadherin and APC, in ulcerative colitis-related colorectal cancers. Mod. Pathol. 14, 29-39 (2001).
46. van Dekken, H. et al. Wnt pathway-related gene expression during malignant progression in ulcerative colitis. Acta Histochem. 109, 266-272 (2007).
47. Dorer, R. & Odze, R. D. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. Am. J. Surg. Pathol. 30, 871-877 (2006).
48. Marx, A. et al. Combined alpha-methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease. Hum. Pathol. 40, 166-173 (2009).
49. Strater, J., Wiesmuller, C., Perner, S., Kuefer, R. & Moller, P. Alpha-methylacyl-CoA racemase (AMACR) immunohistochemistry in Barrett's and colorectal mucosa: Only significant overexpression favours a diagnosis of intraepithelial neoplasia. Histopathology 52, 399-402 (2008).
50. Floren, C. H., Benoni, C. & Willen, R. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand. J. Gastroenterol. 22, 459-462 (1987).
51. Niv, Y., Bat, L., Ron, E. & Theodor, E. Change in the extent of colonic involvement in ulcerative colitis: A colonoscopic study. Am. J. Gastroenterol. 82, 1046-1051 (1987).
52. Mathy, C. et al. Gross versus microscopic pancolitis and the occurrence of neoplasia in ulcerative colitis. Inflamm. Bowel Dis. 9, 351-355 (2003).
53. Yano, Y. et al. Risks and clinical features of colorectal cancer complicating Crohn's disease in Japanese patients. J. Gastroenterol. Hepatol. 23, 1683-1688 (2008).
54. Ekbom, A., Helmick, C., Zack, M. & Adami, H. O. Ulcerative colitis and colorectal cancer. A population-based study. N. Engl. J. Med. 323, 1228-1233 (1990).
55. Askling, J. et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 120, 1356-1362 (2001).
56. Nuako, K. W. et al. Familial predisposition for colorectal cancer in chronic ulcerative colitis: A case-control study. Gastroenterology 115, 1079-1083 (1998).
57. Kornfeld, D., Ekbom, A. & Ihre, T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 41, 522-525 (1997).
58. Thomas, T., Nair, P., Dronfield, M. W. & Mayberry, J. F. Management of low and high-grade dysplasia in inflammatory bowel disease: The gastroenterologists' perspective and current practice in the United Kingdom. Eur. J. Gastroenterol. Hepatol. 17, 1317-1324 (2005).
59. Engelsgjerd, M., Farraye, F. A. & Odze, R. D. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology 117, 1288-1294 (1999).
60. Rubin, P. H. et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology 117, 1295-1300 (1999).
61. ellis, K. K. & Fennerty, M. B. Marking and identifying colon lesions. Tattoos, clips, and radiology in imaging the colon. Gastrointest. Endosc. Clin. N. Am. 7, 401-411 (1997).
62. Shatz, B. A., Weinstock, L. B., Swanson, P. E. & Thyssen, E. P. Long-term safety of India ink tattoos in the colon. Gastrointest. Endosc. 45, 153-156 (1997).
63. Rutter, M. D. et al. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 53, 256-260 (2004).
64. Kiesslich, R. et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 124, 880-888 (2003).
65. Marion, J. F. et al. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: A prospective endoscopic trial. Am. J. Gastroenterol. 103, 2342-2349 (2008).
66. Song, L. M. et al. Narrow band imaging and multiband imaging. Gastrointest. Endosc. 67, 581-589 (2008).
67. Matsumoto, T. et al. Magnifying colonoscopy with narrow band imaging system for the diagnosis of dysplasia in ulcerative colitis: A pilot study. Gastrointest. Endosc. 66, 957-965 (2007).
68. Kuznetsov, K., Lambert, R. & Rey, J. F. Narrow-band imaging: Potential and limitations. Endoscopy 38, 76-81 (2006).
69. Dekker, E. et al. Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy 39, 216-221 (2007).
70. van den Broek, F. J. et al. Endoscopic tri-modal imaging for surveillance in ulcerative colitis: Randomised comparison of high-resolution endoscopy and autofluorescence imaging for neoplasia detection; and evaluation of narrow-band imaging for classification of lesions. Gut 57, 1083-1089 (2008).
71. Kiesslich, R., Goetz, M., Vieth, M., Galle, P. R. & Neurath, M. F. Confocal laser endomicroscopy. Gastrointest. Endosc. Clin. N. Am. 15, 715-731 (2005).
72. Kiesslich, R. et al. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology 132, 874-882 (2007).